Figure 3.

(A) Viabilities of HepG2 and OVSAHO cells treated with 1-OMe-OP. (B) IC50 values (at 72 h) of 1-OMe-OP against HepG2 or OVSAHO cells without/with addition of the inhibitors of esterases: BNPP (nonspecific), loperamide (CES2), and troglitazone (CES1).